MT-134

MT-134 is a preclinical-stage small molecule therapeutic being developed by Myosin Therapeutics for the treatment of an undisclosed musculoskeletal indication. The compound is designed to modulate the activity of non-muscle myosin II (NMII) isoforms, specifically targeting non-muscle myosin IIA (NMIIA, encoded by the MYH9 gene) and non-muscle myosin IIB (NMIIB, encoded by the MYH10 gene). Non-muscle myosins are actin-binding motor proteins that play essential roles in cellular contractility, migration, and structural maintenance. By selectively targeting these isoforms, MT-134 aims to address pathological mechanisms in musculoskeletal disorders where cellular structural integrity and motor protein function are compromised.